Idorsia Ltd. · SIX:IDIA
Idorsia — Technical Presentation (August 2020)
20 slides from Idorsia's technical presentation, Aug 28, 2020
Slide 1: Efficacy and Safety of Daridorexant in Adult and Elderly Patients with Insomnia
Efficacy and Safety of Daridorexant in Adult and Elderly Patients with Insomnia Dr Tom Roth Division of Sleep Medicine and Research Center, Henry Ford Health System, Detroit, USA
Slide 2: Potential Conflict of Interest Disclosure
Type of Potential Conflict Details of Potential Conflict Grant/Research Support n Consultant Eisai, Idorsia, jazz, Merck, Takeda, Philips, Novartis ,seq Speakers’ Bureaus Financial support Other 1. Consultancy agreement between the speaker and Idorsia Pharmaceuticals Ltd 2. 3.
Slide 3: Rationale
Rationale • Daridorexant, a new dual orexin receptor antagonist optimized for onset and duration of action at optimally effective doses, dose-dependently (5–50 mg) improved night- time efficacy, without residual effects, in adult and elderly patients with insomnia in phase 21,2 • These pharmacologic
Slide 4: Objective
Objective • This phase 3 trial was designed to measure the impact of daridorexant on objective and subjective sleep parameters as well as on daytime functioning, and to evaluate safety, in patients with moderate to severe insomnia o Sleep variables were assessed using PSG (WASO, LPS) and a sleep dia
Slide 5: IDSIQ - Insomnia Daytime Symptoms and Impacts Questionnaire
IDSIQ - Insomnia Daytime Symptoms and Impacts Questionnaire Patient-reported outcome instrument validated according to FDA guidance1 Measures • Items are ranked on a NRS scale from 0-10 1 Clear-Headed “Alert/cognition” 19:30 2 Concentrate domain score 3 Forgetful (0-60) 4 Worried 11. How mentally ti
Slide 6: Study Design
Study Design Phase 3, multi-center, double-blind, randomized, placebo-controlled, PSG study Screening 20-31days Treatment Period 84 days Safety Follow-up 30 days Nightly oral DB treatment with placebo or daridorexant 25 mg or 50 mg Daily assessment of sleep and daytime functioning EODBT 1st month 2n
Slide 7: Endpoints
Endpoints Primary efficacy • WASO • LPS Type I error rate (5%) was controlled across Secondary efficacy • sTST the primary and secondary endpoints assessed at Month 1 and Month 3 for each • IDSIQ sleepiness domain active dose (25 and 50 mg) comparison vs placebo (16 comparisons) Other efficacy • IDS
Slide 8: Patient Disposition
Patient Disposition Key entry criteria Adults (18-64 yr) and elderly (≥65 yr) History of sleep-related breathing disorder Insomnia disorder (DSM-5) History of suicidal ideation/attempt ISI score ≥15 Acute/unstable psychiatric conditions (inc. 3326 screened No other sleep disorder depre
Slide 9: Patient Population
Patient Population Daridorexant Daridorexant Placebo 25 mg 50 mg (N=310) (N=310) (N=310) Demographics Female Sex – % 68 69 64 Age – mean ±SD, years 55 ± 15 56 ± 15 56 ± 15 ≥65 – % 39 39 39 Race– % Black or African American 9 6 10 Asian 0 1 1 US region - % 34 32 31 Baseline sleep characteristics, mea
Slide 10: Improvement in WASO
Improvement in WASO Placebo Daridorexant 25 mg Daridorexant 50 mg Two-sided p-values are versus placebo and statistically significant under the control of type I error Mixed effects model for repeated measures adjusted for: baseline value, age group (< 65; ≥ 65 years), treatment, time point, interac
Slide 11: Improvement in LPS
Improvement in LPS Placebo Daridorexant 25 mg Daridorexant 50 mg Two-sided p-values are versus placebo and statistically significant under the control of type I error Mixed effects model for repeated measures adjusted for: baseline value, age group (< 65; ≥ 65 years), treatment, time point, interact
Slide 12: Improvement in sTST
Improvement in sTST Placebo Daridorexant 25 mg Daridorexant 50 mg Two-sided p-values are versus placebo and statistically significant under the control of type I error Mixed effects model for repeated measures adjusted for: baseline value, age group (< 65; ≥ 65 years), treatment, time point, interac
Slide 13: Improvement in IDSIQ Sleepiness/Tiredness Domain Score
Improvement in IDSIQ Sleepiness/Tiredness Domain Score Placebo Daridorexant 25 mg Daridorexant 50 mg Two-sided p-values are versus placebo and for 50 mg (but not 25 mg), are statistically significant under the control of type I error Mixed effects model for repeated measures adjusted for: baseline v
Slide 14: Improvement in Daytime Function
Improvement in Daytime Function IDSIQ total score, mood domain, and alert/cognition domain Total IDSIQ score Alert/cognition domain Mood domain Placebo Daridorexant 25 mg Daridorexant 50 mg Nominal two-sided p-values (versus placebo) are not under type 1 error rate control (not adjusted for multipli
Slide 15: Overall Safety
Overall Safety Adverse events Daridorexant Daridorexant Placebo 25 mg 50 mg No. of patients (%) (N=309) (N=310) (N=308) Patients with ≥1 adverse event 105 (34.0) 117 (37.7) 116 (37.7) Patients with a given adverse event (≥2% in any group) Nasopharyngitis 20 (6.5) 21 (6.8) 20 (6.5) Headache 12 (3.9)
Slide 16: No evidence of Residual Sleepiness in the Morning
No evidence of Residual Sleepiness in the Morning Mean values for VAS morning sleepiness were increased at months 1 and 3 Daridorexant Daridorexant Placebo 25 mg 50 mg VAS morning sleepiness (mm), mean ±SD (N=280) (N=286) (N=286) Baseline 37 ± 19 37 ± 19 38 ± 19 Change from baseline to Month 1 5 ± 1
Slide 17: No evidence of Rebound Insomnia after Termination
No evidence of Rebound Insomnia after Termination Mean values for WASO, LPS, and sTST at run-out were improved from baseline Daridorexant Daridorexant Placebo 25 mg 50 mg (minutes) mean ±SD (N=280) (N=286) (N=286) WASO Change from BL to run-out (V9*) -20.4 ± 45.8 -8.6 ± 55.5 -2.5 ± 52.4 LPS Change f
Slide 18: No evidence of Withdrawal effects
No evidence of Withdrawal effects • BWSQ scores (assessing potential withdrawal) were decreased in all treatment groups at each run-out assessment • No AEs suggestive of withdrawal were observed Daridorexant Daridorexant Placebo 25 mg 50 mg BWSQ score, mean ±SD (N=280) (N=286) (N=286) Last assessmen
Slide 19: Summary
Summary • Daridorexant improved daytime functioning at Month 1 and 3, as measured by reductions in IDSIQ total score and its constituent domains o Daridorexant 50 mg significantly improved sleepiness/tiredness domain scores using the new validated IDSIQ PRO tool, indicating patients felt less sleepy
Slide 20: Acknowledgments
Acknowledgments • The authors would like to thank: • All study investigators (75 sites across 10 countries) • IDMC members: A. Krystal, G.J. Lammers, K. Kim • ISB members: Y. Dauvilliers, G. Plazzi, T. Scammel • The participants, study staff, and nursing teams for their participation in this researc